Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
370 GBX | -.--% | +1.37% | +4.96% |
May. 22 | MaxCyte inks deal with Legend Biotech for tech supply | AN |
May. 22 | MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program | MT |
Financials (USD)
Sales 2024 * | 36.42M | Sales 2025 * | 46.63M | Capitalization | 492M |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | -45M | EV / Sales 2024 * | 9.41 x |
Net cash position 2024 * | 150M | Net cash position 2025 * | 120M | EV / Sales 2025 * | 7.98 x |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-11.2
x | Employees | 143 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.86% |
Latest transcript on MaxCyte, Inc.
1 week | +1.37% | ||
1 month | +25.42% | ||
3 months | -0.67% | ||
6 months | -1.33% | ||
Current year | +4.96% |
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 23-03-26 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 22-11-30 |
Art Mandell
BRD | Director/Board Member | 71 | 06-04-30 |
Will Brooke
BRD | Director/Board Member | 68 | 04-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.20% | 12 M€ | -.--% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 370 | -.--% | 118 |
24-05-30 | 370 | -1.33% | 731 |
24-05-29 | 375 | +3.59% | 36,237 |
24-05-28 | 362 | -0.82% | 17,190 |
24-05-24 | 365 | -0.54% | 1,623 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.96% | 492M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.6B |
- Stock Market
- Equities
- MXCT Stock